Publicaciones en las que colabora con Noelia Casares Lagar (10)

2020

  1. Bivalent therapeutic vaccine against HPV16/18 genotypes consisting of a fusion protein between the extra domain A from human fibronectin and HPV16/18 E7 viral antigens

    Journal for immunotherapy of cancer, Vol. 8, Núm. 1

2013

  1. A fusion protein between streptavidin and the endogenous tlr4 ligand EDA targets biotinylated antigens to dendritic cells and induces t cell responses in vivo

    BioMed Research International, Vol. 2013

2012

  1. Combination of a TLR4 ligand and anaphylatoxin C5a for the induction of antigen-specific cytotoxic T cell responses

    Vaccine, Vol. 30, Núm. 18, pp. 2848-2858

  2. Eradication of large tumors expressing human papillomavirus E7 protein by therapeutic vaccination with E7 fused to the extra domain a from fibronectin

    International Journal of Cancer, Vol. 131, Núm. 3, pp. 641-651

2010

  1. A peptide inhibitor of FOXP3 impairs regulatory T cell activity and improves vaccine efficacy in mice

    Journal of Immunology, Vol. 185, Núm. 9, pp. 5150-5159

2009

  1. Immunization against hepatitis C virus with a fusion protein containing the extra domain A from fibronectin and the hepatitis C virus NS3 protein

    Journal of Hepatology, Vol. 51, Núm. 3, pp. 520-527

2007

  1. The extra domain A from fibronectin targets antigens to TLR4-expressing cells and induces cytotoxic T cell responses in vivo

    Journal of Immunology, Vol. 178, Núm. 2, pp. 748-756

2003

  1. A recombinant adenovirus encoding hepatitis C virus core and E1 proteins protects mice against cytokine-induced liver damage

    Hepatology, Vol. 37, Núm. 2, pp. 461-470

  2. CD4+/CD25+ Regulatory Cells Inhibit Activation of Tumor-Primed CD4+ T Cells with IFN-γ-Dependent Antiangiogenic Activity, as well as Long-Lasting Tumor Immunity Elicited by Peptide Vaccination

    Journal of Immunology, Vol. 171, Núm. 11, pp. 5931-5939

2002

  1. Vaccination with an adenoviral vector encoding hepatitis C virus (HCV) NS3 protein protects against infection with HCV-recombinant vaccinia virus

    Vaccine, Vol. 21, Núm. 3-4, pp. 202-210